CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Abstract: Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are u...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952924007432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849721141370814464 |
|---|---|
| author | Nicola Maciocia Brandon Wade Paul Maciocia |
| author_facet | Nicola Maciocia Brandon Wade Paul Maciocia |
| author_sort | Nicola Maciocia |
| collection | DOAJ |
| description | Abstract: Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area. |
| format | Article |
| id | doaj-art-8bb8835ab8e54e26b8a91f24f3379c16 |
| institution | DOAJ |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-8bb8835ab8e54e26b8a91f24f3379c162025-08-20T03:11:46ZengElsevierBlood Advances2473-95292025-02-019491392310.1182/bloodadvances.2023012263CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?Nicola Maciocia0Brandon Wade1Paul Maciocia2Department of Haematology, University College London Cancer Institute, London, United Kingdom; Correspondence: Nicola Maciocia, Cancer Institute, University College London, 72 Huntley St, London WC1E 6DD, United Kingdom;Department of Haematology, University College London Cancer Institute, London, United KingdomDepartment of Haematology, University College London Cancer Institute, London, United KingdomAbstract: Chimeric antigen receptor T-cell (CAR-T) therapy has proven successful for B-cell lymphomas and leukemias. This success has inspired the development of CAR-T for T-cell malignancies. T-cell lymphomas and T-cell acute lymphoblastic leukemia (T-ALL) are highly heterogenous diseases but are united by poor prognosis in the relapsed/refractory setting and the lack of any novel, targeted therapies. CAR-T therapy is a promising solution for these diseases but carries a number of challenges, principally that target antigens are typically shared between malignant and normal T cells. This can cause issues with fratricide and T-cell aplasia. In this review we discuss the current state of CAR-T treatment for T-ALL and T-cell lymphomas, highlighting recent novel clinical data for T-cell malignancies and discuss lessons that can be learned for future research in this area.http://www.sciencedirect.com/science/article/pii/S2473952924007432 |
| spellingShingle | Nicola Maciocia Brandon Wade Paul Maciocia CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Advances |
| title | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| title_full | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| title_fullStr | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| title_full_unstemmed | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| title_short | CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? |
| title_sort | car t cell therapies for t cell malignancies does cellular immunotherapy represent the best chance of cure |
| url | http://www.sciencedirect.com/science/article/pii/S2473952924007432 |
| work_keys_str_mv | AT nicolamaciocia cartcelltherapiesfortcellmalignanciesdoescellularimmunotherapyrepresentthebestchanceofcure AT brandonwade cartcelltherapiesfortcellmalignanciesdoescellularimmunotherapyrepresentthebestchanceofcure AT paulmaciocia cartcelltherapiesfortcellmalignanciesdoescellularimmunotherapyrepresentthebestchanceofcure |